• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form 1-A/A filed by Scienture Holdings Inc.

    11/5/24 7:14:01 PM ET
    $SCNX
    Other Pharmaceuticals
    Health Care
    Get the next $SCNX alert in real time by email
    schemaVersion:
    Form 1-A Issuer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM 1-A
    REGULATION A OFFERING STATEMENT
    UNDER THE SECURITIES ACT OF 1933
    OMB APPROVAL


    FORM 1-A

    OMB Number:  3235-0286


    Estimated average burden hours per response: 608.0

    1-A: Filer Information

    Issuer CIK
    0001382574 
    Issuer CCC
    XXXXXXXX 
    DOS File Number
     
    Offering File Number
    024-12510 
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST
    Would you like a Return Copy? Checkbox checked
    Notify via Filing Website only? Checkbox not checked
    Since Last Filing? Checkbox not checked

    Submission Contact Information

    Name
     
    Phone
     
    E-Mail Address
     

    1-A: Item 1. Issuer Information

    Issuer Infomation

    Exact name of issuer as specified in the issuer's charter

    Scienture Holdings, Inc. 

    Jurisdiction of Incorporation / Organization

    DELAWARE  

    Year of Incorporation

    2005 

    CIK

    0001382574 

    Primary Standard Industrial Classification Code

    WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES 

    I.R.S. Employer Identification Number

    46-3673928 

    Total number of full-time employees

    14 

    Total number of part-time employees

    5 

    Contact Infomation

    Address of Principal Executive Offices

    Address 1

    6308 Benjamin Road 

    Address 2

    Suite 708 

    City

    Tampa 

    State/Country

    FLORIDA  

    Mailing Zip/ Postal Code

    33634 

    Phone

    866-468-6535 

    Provide the following information for the person the Securities and Exchange Commission's staff should call in connection with any pre-qualification review of the offering statement.

    Name

    Kate Bechen 

    Address 1

     

    Address 2

     

    City

     

    State/Country

     

    Mailing Zip/ Postal Code

     

    Phone

     

    Provide up to two e-mail addresses to which the Securities and Exchange Commission's staff may send any comment letters relating to the offering statement. After qualification of the offering statement, such e-mail addresses are not required to remain active.

    Financial Statements

    Use the financial statements for the most recent period contained in this offering statement to provide the following information about the issuer. The following table does not include all of the line items from the financial statements. Long Term Debt would include notes payable, bonds, mortgages, and similar obligations. To determine "Total Revenues" for all companies selecting "Other" for their industry group, refer to Article 5-03(b)(1) of Regulation S-X. For companies selecting "Insurance", refer to Article 7-04 of Regulation S-X for calculation of "Total Revenues" and paragraphs 5 and 7 of Article 7-04 for "Costs and Expenses Applicable to Revenues".

    Industry Group (select one) Radio button not checked Banking Radio button not checked Insurance Radio button checked Other

    Balance Sheet Information

    Cash and Cash Equivalents

    $ 7719993.00 

    Investment Securities
    $ 2500000.00 
    Total Investments

    $  

    Accounts and Notes Receivable

    $ 13091.00 

    Loans

    $  

    Property, Plant and Equipment (PP&E):

    $ 6500.00 

    Property and Equipment

    $  

    Total Assets

    $ 14848533.00 

    Accounts Payable and Accrued Liabilities

    $ 1226720.00 

    Policy Liabilities and Accruals

    $  

    Deposits

    $  

    Long Term Debt

    $ 160996.00 

    Total Liabilities

    $ 3063085.00 

    Total Stockholders' Equity

    $ 11785448.00 

    Total Liabilities and Equity

    $ 14848533.00 

    Statement of Comprehensive Income Information

    Total Revenues

    $ 18699.00 

    Total Interest Income

    $  

    Costs and Expenses Applicable to Revenues

    $ 19402.00 

    Total Interest Expenses

    $  

    Depreciation and Amortization

    $ 16666.00 

    Net Income

    $ 19412132.00 

    Earnings Per Share - Basic

    $ 15.86 

    Earnings Per Share - Diluted

    $ 13.35 

    Name of Auditor (if any)

    CM3 Advisory 

    Outstanding Securities

    Common Equity

    Name of Class (if any) Common Equity

    Common Stock 

    Common Equity Units Outstanding

    8576795 

    Common Equity CUSIP (if any):

    80880X104 

    Common Equity Units Name of Trading Center or Quotation Medium (if any)

    NASDAQ Capital Market 

    Preferred Equity

    Preferred Equity Name of Class (if any)

    NA 

    Preferred Equity Units Outstanding

    0 

    Preferred Equity CUSIP (if any)

    000000000 

    Preferred Equity Name of Trading Center or Quotation Medium (if any)

    NA 

    Debt Securities

    Debt Securities Name of Class (if any)

    NA 

    Debt Securities Units Outstanding

    0 

    Debt Securities CUSIP (if any):

    000000000 

    Debt Securities Name of Trading Center or Quotation Medium (if any)

    NA 

    1-A: Item 2. Issuer Eligibility

    Issuer Eligibility

    Check this box to certify that all of the following statements are true for the issuer(s)

    Checkbox checked

    • Organized under the laws of the United States or Canada, or any State, Province, Territory or possession thereof, or the District of Columbia.
    • Principal place of business is in the United States or Canada.
    • Not subject to section 13 or 15(d) of the Securities Exchange Act of 1934.
    • Not a development stage company that either (a) has no specific business plan or purpose, or (b) has indicated that its business plan is to merge with an unidentified company or companies.
    • Not an investment company registered or required to be registered under the Investment Company Act of 1940.
    • Not issuing fractional undivided interests in oil or gas rights, or a similar interest in other mineral rights.
    • Not issuing asset-backed securities as defined in Item 1101 (c) of Regulation AB.
    • Not, and has not been, subject to any order of the Commission entered pursuant to Section 12(j) of the Exchange Act (15 U.S.C. 78l(j)) within five years before the filing of this offering statement.
    • Has filed with the Commission all the reports it was required to file, if any, pursuant to Rule 257 during the two years immediately before the filing of the offering statement (or for such shorter period that the issuer was required to file such reports).

    1-A: Item 3. Application of Rule 262

    Application Rule 262

    Check this box to certify that, as of the time of this filing, each person described in Rule 262 of Regulation A is either not disqualified under that rule or is disqualified but has received a waiver of such disqualification.

    Checkbox checked

    Check this box if "bad actor" disclosure under Rule 262(d) is provided in Part II of the offering statement.

    Checkbox not checked

    1-A: Item 4. Summary Information Regarding the Offering and Other Current or Proposed Offerings

    Summary Infomation

    Check the appropriate box to indicate whether you are conducting a Tier 1 or Tier 2 offering Radio button not checked Tier1 Radio button checked Tier2
    Check the appropriate box to indicate whether the financial statements have been audited Radio button not checked Unaudited Radio button checked Audited
    Types of Securities Offered in this Offering Statement (select all that apply)
    Checkbox checkedEquity (common or preferred stock) 
    Does the issuer intend to offer the securities on a delayed or continuous basis pursuant to Rule 251(d)(3)? Radio button checked Yes Radio button not checked No
    Does the issuer intend this offering to last more than one year? Radio button not checked Yes Radio button checked No
    Does the issuer intend to price this offering after qualification pursuant to Rule 253(b)? Radio button checked Yes Radio button not checked No
    Will the issuer be conducting a best efforts offering? Radio button checked Yes Radio button not checked No
    Has the issuer used solicitation of interest communications in connection with the proposed offering? Radio button not checked Yes Radio button checked No
    Does the proposed offering involve the resale of securities by affiliates of the issuer? Radio button not checked Yes Radio button checked No
    Number of securities offered
    1739130 
    Number of securities of that class outstanding
    8576795 

    The information called for by this item below may be omitted if undetermined at the time of filing or submission, except that if a price range has been included in the offering statement, the midpoint of that range must be used to respond. Please refer to Rule 251(a) for the definition of "aggregate offering price" or "aggregate sales" as used in this item. Please leave the field blank if undetermined at this time and include a zero if a particular item is not applicable to the offering.

    Price per security
    $ 11.5000 
    The portion of the aggregate offering price attributable to securities being offered on behalf of the issuer
    $ 20000000.00 
    The portion of the aggregate offering price attributable to securities being offered on behalf of selling securityholders
    $ 0.00 
    The portion of the aggregate offering price attributable to all the securities of the issuer sold pursuant to a qualified offering statement within the 12 months before the qualification of this offering statement
    $ 0.00 
    The estimated portion of aggregate sales attributable to securities that may be sold pursuant to any other qualified offering statement concurrently with securities being sold under this offering statement
    $ 0.00 
    Total (the sum of the aggregate offering price and aggregate sales in the four preceding paragraphs)
    $ 20000000.00 

    Anticipated fees in connection with this offering and names of service providers

    Underwriters - Name of Service Provider
    Aegis Capital Corp.
    Underwriters - Fees
    $ 75000.00 
    Sales Commissions - Name of Service Provider
    Aegis Capital Corp.
    Sales Commissions - Fee
    $ 1400000.00 
    Finders' Fees - Name of Service Provider
    None
    Finders' Fees - Fees
    $ 0.00 
    Accounting or Audit - Name of Service Provider
    CM3 Advisory
    Accounting or Audit - Fees
    $ 7500.00 
    Legal - Name of Service Provider
    Dykema Gossett PLLC
    Legal - Fees
    $ 125000.00 
    Promoters - Name of Service Provider
    None
    Promoters - Fees
    $ 0.00 
    Blue Sky Compliance - Name of Service Provider
    None
    Blue Sky Compliance - Fees
    $ 0.00 
    CRD Number of any broker or dealer listed:
    000015007 
    Estimated net proceeds to the issuer
    $ 18392500.00 
    Clarification of responses (if necessary)
     

    1-A: Item 5. Jurisdictions in Which Securities are to be Offered

    Jurisdictions in Which Securities are to be Offered

    Using the list below, select the jurisdictions in which the issuer intends to offer the securities

    Selected States and Jurisdictions

    DELAWARE
    NEW YORK
    CANADA (FEDERAL LEVEL)

    Using the list below, select the jurisdictions in which the securities are to be offered by underwriters, dealers or sales persons or check the appropriate box

    None Checkbox not checked
    Same as the jurisdictions in which the issuer intends to offer the securities Checkbox checked
    Selected States and Jurisdictions

    DELAWARE
    NEW YORK
    CANADA (FEDERAL LEVEL)

    1-A: Item 6. Unregistered Securities Issued or Sold Within One Year

    Unregistered Securities Issued or Sold Within One Year

    None Checkbox not checked

    Unregistered Securities Issued

    As to any unregistered securities issued by the issuer of any of its predecessors or affiliated issuers within one year before the filing of this Form 1-A, state:

    (a)Name of such issuer
    Scienture Holdings, Inc. (f/k/a TRxADE HEALTH, Inc.) 
    (b)(1) Title of securities issued
    Convertible Promissory Note and Common Stock Purchase Warrants
     
    (2) Total Amount of such securities issued
    360000
    (3) Amount of such securities sold by or for the account of any person who at the time was a director, officer, promoter or principal securityholder of the issuer of such securities, or was an underwriter of any securities of such issuer.
    0 
    (c)(1) Aggregate consideration for which the securities were issued and basis for computing the amount thereof.
    $324,000 pursuant to that certain Stock Purchase Agreement dated August 19, 2024, by and between Scienture Holdings, LLC (f/k/a TRxADE HEALTH, Inc.) and Hudson Global Ventures, LLC.
     
    (2) Aggregate consideration for which the securities listed in (b)(3) of this item (if any) were issued and the basis for computing the amount thereof (if different from the basis described in (c)(1)).
     

    Unregistered Securities Issued

    As to any unregistered securities issued by the issuer of any of its predecessors or affiliated issuers within one year before the filing of this Form 1-A, state:

    (a)Name of such issuer
    Scienture Holdings, Inc. (f/k/a TRxADE HEALTH, Inc.) 
    (b)(1) Title of securities issued
    Series C Preferred Stock and Common Stock Warrant
     
    (2) Total Amount of such securities issued
    290000
    (3) Amount of such securities sold by or for the account of any person who at the time was a director, officer, promoter or principal securityholder of the issuer of such securities, or was an underwriter of any securities of such issuer.
    0 
    (c)(1) Aggregate consideration for which the securities were issued and basis for computing the amount thereof.
    $290,000 pursuant to that certain Securities Purchase Agreement dated October 4, 2023, by and between Scienture Holdings, LLC (f/k/a TRxADE HEALTH, Inc.) and Hudson Global Ventures, LLC.
     
    (2) Aggregate consideration for which the securities listed in (b)(3) of this item (if any) were issued and the basis for computing the amount thereof (if different from the basis described in (c)(1)).
     

    Unregistered Securities Issued

    As to any unregistered securities issued by the issuer of any of its predecessors or affiliated issuers within one year before the filing of this Form 1-A, state:

    (a)Name of such issuer
    Scienture Holdings, Inc. (f/k/a TRxADE HEALTH, Inc.) 
    (b)(1) Title of securities issued
    Common Stock and Series X Preferred Stock
     
    (2) Total Amount of such securities issued
    7118268
    (3) Amount of such securities sold by or for the account of any person who at the time was a director, officer, promoter or principal securityholder of the issuer of such securities, or was an underwriter of any securities of such issuer.
    0 
    (c)(1) Aggregate consideration for which the securities were issued and basis for computing the amount thereof.
    $83,670,000 pursuant to that certain Agreement and Plan of Merger dated July 25, 2024, by and between Scienture Holdings, Inc. (f/k/a TRxADE HEALTH, Inc.), MEDS Merger Sub I, Inc., MEDS Merger Sub II, LLC, and Scienture, Inc.
     
    (2) Aggregate consideration for which the securities listed in (b)(3) of this item (if any) were issued and the basis for computing the amount thereof (if different from the basis described in (c)(1)).
     

    Unregistered Securities Act

    (d) Indicate the section of the Securities Act or Commission rule or regulation relied upon for exemption from the registration requirements of such Act and state briefly the facts relied upon for such exemption
    Section 4(a)(2) of the Securities Act
     
    Get the next $SCNX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SCNX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SCNX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium

    Company highlights accelerating access and revenue growth for ARBLI™ and confirms REZENOPY™ launch timeline, addressing a combined US annual losartan and naloxone market size of close to $385 million Outlines Q1 2026 outlook and reports significant balance sheet improvement last quarter COMMACK, NY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided a commercial update on ARBLI™ (

    2/3/26 8:05:00 AM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment

    U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually COMMACK, NY, Jan. 14, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,514,854 B2, an Orange Book-listable patent covering REZENOPY™ (naloxone HCl) Nasal Spray 10 mg, effective January 6, 2026, with an expiry date of February

    1/14/26 8:05:00 AM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA

    U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually COMMACK, NY, Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided an update on the commercial launch of REZENOPY®. As previously disclosed, Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. entered into a definitive agreement with Summit Biosciences Inc. (a Kindeva subsidiary) in M

    12/22/25 8:05:00 AM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    $SCNX
    SEC Filings

    View All

    Scienture Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Scienture Holdings, Inc. (0001382574) (Filer)

    11/14/25 5:00:35 PM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    Scienture Holdings Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Scienture Holdings, Inc. (0001382574) (Filer)

    11/13/25 5:00:35 PM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    SEC Form 10-Q filed by Scienture Holdings Inc.

    10-Q - Scienture Holdings, Inc. (0001382574) (Filer)

    11/12/25 5:30:11 PM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    $SCNX
    Leadership Updates

    Live Leadership Updates

    View All

    SCIENTURE Announces Executive Leadership Transition

    TAMPA, FL, May 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) (the "Company"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that Suren Ajjarapu, who has served as Chief Executive Officer (CEO) and Chairman of the Board of Directors (BOD), has stepped down from his roles with the Company, with those positions being assumed by the existing, experienced management team of Dr. Shankar Hariharan and Dr. Narasimhan Mani. Shankar Hariharan, P

    5/22/25 8:05:00 AM ET
    $SCNX
    Other Pharmaceuticals
    Health Care